SEC Form 4 · accession 0001171843-17-003479
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Johnson
Director
Period of report
Jun 1, 2017
Accepted (ET)
Jun 5, 2017 · 9:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2017 | A | 5,130 | $0.00 | A | 14,930 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $10.30 | Jun 1, 2017 | A | 10,000 | A | — | Jun 1, 2027 | Class A Common Stock | 10,000 | 60,000 | D |
Explanation of responses
- F1Common stock granted consists of restricted stock units that vest in a single installment on June 1, 2018.
- F2Vesting commences July 1, 2017 in 12-monthly installments.